- Clinical-stage biotech biopharmaceutical company Legend Biotech Corporation ( NASDAQ: LEGN ) announced on Thursday that the company ended its Phase 1 Clinical Trial for CAR-T candidate LB1901 involving adults with relapsed or refractory T-cell lymphoma.
- Legend ( LEGN ) notified the FDA in this regard on July 06, the management said in a regulatory submission, referring to the Investigational New Drug (IND) application for the autologous chimeric antigen receptor T-cell therapy.
- The termination of the trial follows the lack of clinical benefit seen in a similar CAR-T candidate expressing the same CAR protein as LB1901, the company said, adding that prioritization of other candidates in the pipeline also led to the decision.
For further details see:
Legend Biotech ends Phase 1 trial for lymphoma candidate